Jaekwang Jeong

Jaekwang Jeong

Auto-generated profile, based on publicly available information

Jaekwang Jeong

Section of Endocrinology and Metabolism, Department of Internal Medicine, Yale University School of Medicine, New Haven, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JSJae Hun Shin
Jae Hun Shin
JJJaekwang Jeong
Jaekwang Jeong
SMStephen E. Maher
Stephen E. Maher
HLHeon-Woo Lee
Heon-Woo Lee
JLJaechul Lim
Jaechul Lim
ABAlfred Lester Meador Bothwell
Alfred Lester Meador Bothwell
Cancer cells can develop an immunosuppressive tumor microenvironment to control tumor-infiltrating lymphocytes. The underlying mechanisms still remain unclear. Here, we report that mouse and human colon cancer cells acquire lymphocyte membrane proteins including cellular markers such as CD4 and CD45. We observed cell populations harboring both a tumor-specific marker and CD4 in the tumor microenvironment. Sorted cells from these populations were capable of forming organoids, identifying them as cancer cells. Live imaging analysis revealed that lymphocyte membrane proteins were transferred to cancer cells via trogocytosis. As a result of the transfer in vivo, cancer cells also acquired immune regulatory surface proteins such as CTLA4 and Tim3, which suppress activation of immune cells [T. L. Walunas et al., Immunity 1, 405–413 (1994) and L. Monney et al., Nature 415, 536–541 (2002)]. RNA sequencing analysis of ex vivo–cocultured splenocytes with trogocytic cancer cells showed reductions in Th1 activation and natural killer cell signaling pathways compared with the nontrogocytic control. Cancer cell trogocytosis was confirmed in the patient-derived xenograft models of colorectal cancer and head and neck cancer. These findings suggest that cancer cells utilize membrane proteins expressed in lymphocytes, which in turn contribute to the development of the immunosuppressive tumor microenvironment. Significance We have identified the presence of cancer cells harboring immune cell–specific surface marker proteins such as CD4 in the tumor microenvironment. Cancer cells acquired not only the T cell marker protein CD4 but also immune regulatory molecules such as CTLA4 by trogocytosis. Unlike other endocytic mechanisms, trogocytosis maintains the cellular localization and functions of the transferred membrane proteins. Therefore, trogocytic transfer of immune regulatory molecules enhances the immunosuppressive functions of cancer cells. This study provides insight into the interactions between cancer cells and tumor-infiltrating immune cells and how they contribute to the development of the immunosuppressive tumor microenvironment.

1 January 2019 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
JJJaekwang Jeong
Jaekwang Jeong
JCJungmin Choi
Jungmin Choi
WKWonnam Kim
Wonnam Kim
PDPamela Dann
Pamela Dann
FTFarzin Takyar
Farzin Takyar
JWJohn J. Wysolmerski
John J. Wysolmerski
Unlike other ErbB family members, HER2 levels are maintained on the cell surface when the receptor is activated, allowing prolonged signaling and contributing to its transforming ability. Interactions between HER2, HSP90, PMCA2 and NHERF1 within specialized plasma membrane domains contribute to the membrane retention of HER2. We hypothesized that the scaffolding protein, ezrin, which has been shown to interact with NHERF1, might also help stabilize the HER2/PMCA2/NHERF1 complex at the plasma membrane. Therefore, we examined ezrin expression and its relationship to HER2, NHERF1 and PMCA2 levels in murine and human breast cancers. We also used genetic knockdown and/or pharmacologic inhibition of ezrin, HSP90, NHERF1, PMCA2 and HER2 to examine the functional relationships between these factors and membrane retention of HER2. We found ezrin to be expressed at low levels at the apical surface of normal mammary epithelial cells, but its expression is upregulated and correlates with HER2 expression in hyperplasia and tumors in MMTV-Neu mice, in human HER2-positive breast cancer cell lines and in DCIS and invasive breast cancers from human patients. In breast cancer cells, ezrin co-localizes and interacts with HER2, NHERF1, PMCA2 and HSP90 in specialized membrane domains, and inhibiting ezrin disrupts interactions between HER2, PMCA2, NHERF1 and HSP90, thereby inhibiting HER2 signaling, and causing PKCa-mediated internalization and degradation of HER2. Inhibition of ezrin synergizes with lapatinib in a PKCa-dependent fashion to inhibit proliferation and promote apoptosis in HER2-positive breast cancer cells. We conclude that ezrin stabilizes a multiprotein complex that maintains active HER2 at the cell surface.

1 December 2021 in Cell Reports
Verified
Journal Article
Open access
JJJaekwang Jeong
Jaekwang Jeong
JSJae Hun Shin
Jae Hun Shin
WLWenxue Li
Wenxue Li
JHJun Young Hong
Jun Young Hong
JLJaechul Lim
Jaechul Lim
JWJohn Wysolmerski
John Wysolmerski
The lipid raft-resident protein, MAL2, has been implicated as contributing to the pathogenesis of several malignancies, including breast cancer, but the underlying mechanism for its effects on tumorigenesis is unknown. Here, we show that MAL2-mediated lipid raft formation leads to HER2 plasma membrane retention and enhanced HER2 signaling in breast cancer cells. We demonstrate physical interactions between HER2 and MAL2 in lipid rafts using proximity ligation assays. Super-resolution structured illumination microscopy imaging displays the structural organization of the HER2/Ezrin/NHERF1/PMCA2 protein complex. Formation of this protein complex maintains low intracellular calcium concentrations in the vicinity of the plasma membrane. HER2/MAL2 protein interactions in lipid rafts are enhanced in trastuzumab-resistant breast cancer cells. Our findings suggest that MAL2 is crucial for lipid raft formation, HER2 signaling, and HER2 membrane stability in breast cancer cells, suggesting MAL2 as a potential therapeutic target.

6 October 2021 in Cells
Verified
Journal Article
Open access
PDF file
YPYoungJoon Park
YoungJoon Park
JJJaekwang Jeong
Jaekwang Jeong
SSShin Seong
Shin Seong
WKWonnam Kim
Wonnam Kim
The survival rates for breast cancer (BC) have improved in recent years, but resistance, metastasis, and recurrence still remain major therapeutic challenges for BC. The acidic tumor microenvironment (TME) has attracted attention because of its association with tumorigenesis, metastasis, drug resistance, and immune surveillance. In this study, we evaluated natural compounds from traditional herbal medicine used to treat cancer that selectively target genes regulated by extracellular acidosis. We integrated four transcriptomic data including BC prognostic data from The Cancer Genome Atlas database, gene expression profiles of MCF-7 cells treated with 102 natural compounds, patterns of gene profiles by acidic condition, and single-cell RNA-sequencing from BC patient samples. Bruceine D (BD) was predicted as having the highest therapeutic potential, having an information gain (IG) score of 0.24, to regulate reprogrammed genes driven by acidosis affecting the survival of BC patients. BD showed the highest IG on EMT (IG score: 0.11) and invasion (IG score: 0.1) compared to the other phenotypes with the CancerSEA database. BD also demonstrated therapeutic potential by interfering with the tumor cell–TME interactions by reducing the amyloid beta precursor protein and CD44 expression. Therefore, BD is a potential candidate to target the acidic TME induced metastatic process in BC.

14 May 2019 in Endocrinology
Verified
Journal Article
Open access
PDF file
JJJaekwong Jeong
Jaekwong Jeong
WKWonnam Kim
Wonnam Kim
JHJulie Hens
Julie Hens
PDPamela Dann
Pamela Dann
PSPepper Schedin
Pepper Schedin
JWJohn J Wysolmerski
John J Wysolmerski
Prior studies have demonstrated that the calcium pump, plasma membrane calcium ATPase 2 (PMCA2), mediates calcium transport into milk and prevents mammary epithelial cell death during lactation. PMCA2 also regulates cell proliferation and cell death in breast cancer cells, in part by maintaining the receptor tyrosine kinase ErbB2/HER2 within specialized plasma membrane domains. Furthermore, the regulation of PMCA2 membrane localization and activity in breast cancer cells requires its interaction with the PDZ domain–containing scaffolding molecule sodium-hydrogen exchanger regulatory factor (NHERF) 1. In this study, we asked whether NHERF1 also interacts with PMCA2 in normal mammary epithelial cells during lactation. Our results demonstrate that NHERF1 expression is upregulated during lactation and that it interacts with PMCA2 at the apical membrane of secretory luminal epithelial cells. Similar to PMCA2, NHERF1 expression is rapidly reduced by milk stasis after weaning. Examining lactating NHERF1 knockout (KO) mice showed that NHERF1 contributes to the proper apical location of PMCA2, for proper apical–basal polarity in luminal epithelial cells, and that it participates in the suppression of Stat3 activation and the prevention of premature mammary gland involution. Additionally, we found that PMCA2 also interacts with the closely related scaffolding molecule, NHERF2, at the apical membrane, which likely maintains PMCA2 at the plasma membrane of mammary epithelial cells in lactating NHERF1KO mice. Based on these data, we conclude that, during lactation, NHERF1 is required for the proper expression and apical localization of PMCA2, which, in turn, contributes to preventing the premature activation of Stat3 and the lysosome-mediated cell death pathway that usually occur only early in mammary involution.

1 December 2020 in Current Opinion in Endocrine and Metabolic Research
Verified
Journal Article
Closed access
DGDiego Grinman
Diego Grinman
DADiana AthonvarAngkul
Diana AthonvarAngkul
JWJohn Wysolmerski
John Wysolmerski
JJJaekwang Jeong
Jaekwang Jeong